ID   ZCCHV_HUMAN             Reviewed;         902 AA.
AC   Q7Z2W4; A4D1R2; A4D1S4; Q8IW57; Q8TAJ3; Q96N79; Q9H8R9; Q9P0Y7;
DT   10-MAY-2004, integrated into UniProtKB/Swiss-Prot.
DT   10-FEB-2009, sequence version 3.
DT   10-MAY-2017, entry version 139.
DE   RecName: Full=Zinc finger CCCH-type antiviral protein 1;
DE   AltName: Full=ADP-ribosyltransferase diphtheria toxin-like 13;
DE            Short=ARTD13;
DE   AltName: Full=Zinc finger CCCH domain-containing protein 2;
DE   AltName: Full=Zinc finger antiviral protein;
DE            Short=ZAP;
GN   Name=ZC3HAV1; Synonyms=ZC3HDC2; ORFNames=PRO1677;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5), AND VARIANT
RP   GLN-565.
RC   TISSUE=Fetal liver;
RA   Zhang C., Yu Y., Zhang S., Zhou G., Wei H., Bi J., Xu W., Zai Y.,
RA   Feng F., Liu M., He F.;
RT   "Functional prediction of the coding sequences of 5 new genes deduced
RT   by analysis of cDNA clones from human fetal liver.";
RL   Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4), AND
RP   VARIANTS LYS-485; GLN-565 AND GLU-701.
RC   TISSUE=Kidney, and Ovarian carcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS
RP   GLU-701 AND ILE-851.
RC   TISSUE=Endometrium;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S.,
RA   Kwasnicka D., Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z.,
RA   Lu F., Zeesman S., Nowaczyk M.J., Teshima I., Chitayat D., Shuman C.,
RA   Weksberg R., Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J.,
RA   Rahman N., Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F.,
RA   Belloni E., Shaffer L.G., Pober B., Morton C.C., Gusella J.F.,
RA   Bruns G.A.P., Korf B.R., Quade B.J., Ligon A.H., Ferguson H.,
RA   Higgins A.W., Leach N.T., Herrick S.R., Lemyre E., Farra C.G.,
RA   Kim H.-G., Summers A.M., Gripp K.W., Roberts W., Szatmari P.,
RA   Winsor E.J.T., Grzeschik K.-H., Teebi A., Minassian B.A., Kere J.,
RA   Armengol L., Pujana M.A., Estivill X., Wilson M.D., Koop B.F.,
RA   Tosi S., Moore G.E., Boright A.P., Zlotorynski E., Kerem B.,
RA   Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W.,
RA   Mural R.J., Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND
RP   VARIANTS GLU-701 AND ILE-851.
RC   TISSUE=Brain, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-284, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-284, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-284, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [11]
RP   FUNCTION.
RX   PubMed=18225958; DOI=10.1371/journal.pgen.0040021;
RA   Kerns J.A., Emerman M., Malik H.S.;
RT   "Positive selection and increased antiviral activity associated with
RT   the PARP-containing isoform of human zinc-finger antiviral protein.";
RL   PLoS Genet. 4:E21-E21(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-271; THR-273; SER-275;
RP   SER-284; SER-302; SER-378; SER-387 AND THR-393, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   REVIEW.
RX   PubMed=18418085; DOI=10.4161/rna.5.2.6044;
RA   Zhu Y., Gao G.;
RT   "ZAP-mediated mRNA degradation.";
RL   RNA Biol. 5:65-67(2008).
RN   [14]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-257; SER-284; SER-335;
RP   SER-387 AND THR-393, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY, BIOPHYSICOCHEMICAL PROPERTIES,
RP   RNA-BINDING, AND DOMAIN N-TERMINAL.
RX   PubMed=20451500; DOI=10.1016/j.bbrc.2010.04.164;
RA   Jeong M.S., Kim E.J., Jang S.B.;
RT   "Expression and RNA-binding of human zinc-finger antiviral protein.";
RL   Biochem. Biophys. Res. Commun. 396:696-702(2010).
RN   [17]
RP   SUBUNIT.
RX   PubMed=20181706; DOI=10.1128/JVI.02018-09;
RA   Law L.M., Albin O.R., Carroll J.W., Jones C.T., Rice C.M.,
RA   Macdonald M.R.;
RT   "Identification of a dominant negative inhibitor of human zinc finger
RT   antiviral protein reveals a functional endogenous pool and critical
RT   homotypic interactions.";
RL   J. Virol. 84:4504-4512(2010).
RN   [18]
RP   INTERACTION WITH DHX30.
RX   PubMed=21204022; DOI=10.1007/s13238-010-0117-8;
RA   Ye P., Liu S., Zhu Y., Chen G., Gao G.;
RT   "DEXH-Box protein DHX30 is required for optimal function of the zinc-
RT   finger antiviral protein.";
RL   Protein Cell 1:956-964(2010).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-284; SER-302; SER-335;
RP   SER-378; THR-393 AND SER-492, PHOSPHORYLATION [LARGE SCALE ANALYSIS]
RP   AT SER-572 (ISOFORM 3), AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [20]
RP   NOMENCLATURE.
RX   PubMed=20106667; DOI=10.1016/j.tibs.2009.12.003;
RA   Hottiger M.O., Hassa P.O., Luscher B., Schuler H., Koch-Nolte F.;
RT   "Toward a unified nomenclature for mammalian ADP-
RT   ribosyltransferases.";
RL   Trends Biochem. Sci. 35:208-219(2010).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [22]
RP   REVIEW.
RX   PubMed=21169998; DOI=10.1038/ni0111-11;
RA   Liu H.M., Gale M. Jr.;
RT   "ZAPS electrifies RIG-I signaling.";
RL   Nat. Immunol. 12:11-12(2011).
RN   [23]
RP   FUNCTION, SUBCELLULAR LOCATION, INDUCTION, AND INTERACTION WITH
RP   DDX58/RIG-I.
RX   PubMed=21102435; DOI=10.1038/ni.1963;
RA   Hayakawa S., Shiratori S., Yamato H., Kameyama T., Kitatsuji C.,
RA   Kashigi F., Goto S., Kameoka S., Fujikura D., Yamada T., Mizutani T.,
RA   Kazumata M., Sato M., Tanaka J., Asaka M., Ohba Y., Miyazaki T.,
RA   Imamura M., Takaoka A.;
RT   "ZAPS is a potent stimulator of signaling mediated by the RNA helicase
RT   RIG-I during antiviral responses.";
RL   Nat. Immunol. 12:37-44(2011).
RN   [24]
RP   FUNCTION, AND INTERACTION WITH EXOSC3; EXOSC7; PARN; DCP2; DCP1A AND
RP   XRN1.
RX   PubMed=21876179; DOI=10.1073/pnas.1101676108;
RA   Zhu Y., Chen G., Lv F., Wang X., Ji X., Xu Y., Sun J., Wu L.,
RA   Zheng Y.T., Gao G.;
RT   "Zinc-finger antiviral protein inhibits HIV-1 infection by selectively
RT   targeting multiply spliced viral mRNAs for degradation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:15834-15839(2011).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-284, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [26]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [27]
RP   FUNCTION.
RX   PubMed=22720057; DOI=10.1371/journal.pone.0039159;
RA   Wang X., Tu F., Zhu Y., Gao G.;
RT   "Zinc-finger antiviral protein inhibits XMRV infection.";
RL   PLoS ONE 7:E39159-E39159(2012).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-257; THR-273; SER-275;
RP   SER-284; SER-302; SER-335; SER-355; SER-378; THR-393; SER-407;
RP   SER-469; SER-492; SER-494; THR-554 AND SER-590, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-275; SER-284 AND
RP   SER-492, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (1.05 ANGSTROMS) OF 724-896, DOMAIN, AND
RP   MUTAGENESIS OF HIS-810 AND ASN-830.
RX   PubMed=25635049; DOI=10.1074/jbc.M114.630160;
RA   Karlberg T., Klepsch M., Thorsell A.G., Andersson C.D., Linusson A.,
RA   Schuler H.;
RT   "Structural basis for lack of ADP-ribosyltransferase activity in
RT   poly(ADP-ribose) polymerase-13/zinc finger antiviral protein.";
RL   J. Biol. Chem. 290:7336-7344(2015).
CC   -!- FUNCTION: Antiviral protein which inhibits the replication of
CC       viruses by recruiting the cellular RNA degradation machineries to
CC       degrade the viral mRNAs. Binds to a ZAP-responsive element (ZRE)
CC       present in the target viral mRNA, recruits cellular poly(A)-
CC       specific ribonuclease PARN to remove the poly(A) tail, and the 3'-
CC       5' exoribonuclease complex exosome to degrade the RNA body from
CC       the 3'-end. It also recruits the decapping complex DCP1-DCP2
CC       through RNA helicase p72 (DDX17) to remove the cap structure of
CC       the viral mRNA to initiate its degradation from the 5'-end. Its
CC       target viruses belong to families which include retroviridae:
CC       human immunodeficiency virus type 1 (HIV-1), moloney and murine
CC       leukemia virus (MoMLV) and xenotropic MuLV-related virus (XMRV),
CC       filoviridae: ebola virus (EBOV) and marburg virus (MARV),
CC       togaviridae: sindbis virus (SINV) and Ross river virus (RRV).
CC       Specifically targets the multiply spliced but not unspliced or
CC       singly spliced HIV-1 mRNAs for degradation. Isoform 1 is a more
CC       potent viral inhibitor than isoform 2. Isoform 2 acts as a
CC       positive regulator of DDX58/RIG-I signaling resulting in
CC       activation of the downstream effector IRF3 leading to the
CC       expression of type I IFNs and IFN stimulated genes (ISGs).
CC       {ECO:0000269|PubMed:18225958, ECO:0000269|PubMed:21102435,
CC       ECO:0000269|PubMed:21876179, ECO:0000269|PubMed:22720057}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Temperature dependence:
CC         Thermostable. {ECO:0000269|PubMed:20451500};
CC   -!- SUBUNIT: Homodimer or homooligomer. Homooligomerization is
CC       essential for its antiviral activity. Interacts with EXOSC5 (By
CC       similarity). Interacts (via N-terminal domain) with DDX17 in an
CC       RNA-independent manner (By similarity). Interacts with EXOSC3,
CC       EXOSC7, DCP2 and DCP1A. Interacts with PARN in an RNA-independent
CC       manner. Interacts with XRN1 in an RNA-dependent manner. Isoform 2
CC       interacts (via zinc-fingers) with DDX58/RIG-I in an RNA-dependent
CC       manner. Interacts (via N-terminal domain) with DHX30 (via N-
CC       terminus) in an RNA-independent manner. {ECO:0000250,
CC       ECO:0000269|PubMed:20181706, ECO:0000269|PubMed:21102435,
CC       ECO:0000269|PubMed:21204022, ECO:0000269|PubMed:21876179}.
CC   -!- INTERACTION:
CC       O95786:DDX58; NbExp=4; IntAct=EBI-922559, EBI-995350;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cytoplasm. Nucleus.
CC       Note=Localizes in the cytoplasm at steady state, but shuttles
CC       between nucleus and cytoplasm in a XPO1-dependent manner.
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=ZAPL;
CC         IsoId=Q7Z2W4-1; Sequence=Displayed;
CC       Name=2; Synonyms=ZAPS;
CC         IsoId=Q7Z2W4-2; Sequence=VSP_010269;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q7Z2W4-3; Sequence=VSP_010270, VSP_010271;
CC         Note=No experimental confirmation available. Contains a
CC         phosphoserine at position 572. {ECO:0000244|PubMed:20068231};
CC       Name=4;
CC         IsoId=Q7Z2W4-4; Sequence=VSP_010268;
CC         Note=No experimental confirmation available.;
CC       Name=5;
CC         IsoId=Q7Z2W4-5; Sequence=VSP_010268, VSP_010269;
CC         Note=No experimental confirmation available.;
CC   -!- INDUCTION: By type I interferon (IFN) and viruses. Isoform 2 is
CC       up-regulated by 3'-PPP-RNA. {ECO:0000269|PubMed:21102435}.
CC   -!- DOMAIN: The N-terminal domain is sufficient to bind to viral RNAs
CC       and promote their degradation. The second and fourth zinc fingers
CC       are involved in binding to specific viral RNAs (PubMed:20451500).
CC       Contains a divergent PARP homology ADP-ribosyltransferase domain
CC       which lacks the structural requirements for NAD[+] binding. It is
CC       therefore inactive (PubMed:25635049).
CC       {ECO:0000269|PubMed:20451500, ECO:0000269|PubMed:25635049}.
CC   -!- PTM: Phosphorylation at Ser-275 is essential for sequential
CC       phosphorylation of Ser-271, Ser-267, Ser-263 and Ser-257 by GSK3-
CC       beta. Phosphorylation by GSK3-beta enhances its antiviral activity
CC       (By similarity). {ECO:0000250}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF138863; AAF61195.1; -; mRNA.
DR   EMBL; AK055851; BAB71028.1; -; mRNA.
DR   EMBL; AK023350; BAB14537.1; -; mRNA.
DR   EMBL; BX571742; CAE11868.1; -; mRNA.
DR   EMBL; CH236950; EAL24040.1; -; Genomic_DNA.
DR   EMBL; CH236950; EAL24041.1; -; Genomic_DNA.
DR   EMBL; BC025308; AAH25308.1; -; mRNA.
DR   EMBL; BC027462; AAH27462.1; -; mRNA.
DR   EMBL; BC033105; AAH33105.1; -; mRNA.
DR   EMBL; BC040956; AAH40956.1; -; mRNA.
DR   CCDS; CCDS55171.1; -. [Q7Z2W4-2]
DR   CCDS; CCDS5851.1; -. [Q7Z2W4-1]
DR   RefSeq; NP_064504.2; NM_020119.3. [Q7Z2W4-1]
DR   RefSeq; NP_078901.3; NM_024625.3. [Q7Z2W4-2]
DR   UniGene; Hs.133512; -.
DR   PDB; 2X5Y; X-ray; 1.05 A; A=724-896.
DR   PDB; 4X52; X-ray; 2.08 A; A/B/C/D=726-896.
DR   PDBsum; 2X5Y; -.
DR   PDBsum; 4X52; -.
DR   ProteinModelPortal; Q7Z2W4; -.
DR   SMR; Q7Z2W4; -.
DR   BioGrid; 121203; 132.
DR   DIP; DIP-37896N; -.
DR   IntAct; Q7Z2W4; 18.
DR   MINT; MINT-5006396; -.
DR   STRING; 9606.ENSP00000242351; -.
DR   iPTMnet; Q7Z2W4; -.
DR   PhosphoSitePlus; Q7Z2W4; -.
DR   SwissPalm; Q7Z2W4; -.
DR   BioMuta; ZC3HAV1; -.
DR   DMDM; 223634727; -.
DR   EPD; Q7Z2W4; -.
DR   MaxQB; Q7Z2W4; -.
DR   PaxDb; Q7Z2W4; -.
DR   PeptideAtlas; Q7Z2W4; -.
DR   PRIDE; Q7Z2W4; -.
DR   Ensembl; ENST00000242351; ENSP00000242351; ENSG00000105939. [Q7Z2W4-1]
DR   Ensembl; ENST00000471652; ENSP00000419855; ENSG00000105939. [Q7Z2W4-2]
DR   GeneID; 56829; -.
DR   KEGG; hsa:56829; -.
DR   UCSC; uc003vun.4; human. [Q7Z2W4-1]
DR   CTD; 56829; -.
DR   DisGeNET; 56829; -.
DR   GeneCards; ZC3HAV1; -.
DR   H-InvDB; HIX0007129; -.
DR   HGNC; HGNC:23721; ZC3HAV1.
DR   HPA; HPA047818; -.
DR   HPA; HPA059096; -.
DR   MIM; 607312; gene.
DR   neXtProt; NX_Q7Z2W4; -.
DR   OpenTargets; ENSG00000105939; -.
DR   PharmGKB; PA134944289; -.
DR   eggNOG; ENOG410IEI4; Eukaryota.
DR   eggNOG; ENOG410ZFB8; LUCA.
DR   GeneTree; ENSGT00760000119084; -.
DR   HOVERGEN; HBG050384; -.
DR   InParanoid; Q7Z2W4; -.
DR   KO; K15259; -.
DR   PhylomeDB; Q7Z2W4; -.
DR   TreeFam; TF338389; -.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF fusions.
DR   ChiTaRS; ZC3HAV1; human.
DR   EvolutionaryTrace; Q7Z2W4; -.
DR   GeneWiki; ZC3HAV1; -.
DR   GenomeRNAi; 56829; -.
DR   PMAP-CutDB; Q7Z2W4; -.
DR   PRO; PR:Q7Z2W4; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000105939; -.
DR   CleanEx; HS_ZC3HAV1; -.
DR   ExpressionAtlas; Q7Z2W4; baseline and differential.
DR   Genevisible; Q7Z2W4; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005770; C:late endosome; IEA:Ensembl.
DR   GO; GO:0005764; C:lysosome; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0045296; F:cadherin binding; IDA:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003950; F:NAD+ ADP-ribosyltransferase activity; IEA:InterPro.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0071360; P:cellular response to exogenous dsRNA; IEA:Ensembl.
DR   GO; GO:0051607; P:defense response to virus; IEA:UniProtKB-KW.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0045071; P:negative regulation of viral genome replication; IDA:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IMP:UniProtKB.
DR   GO; GO:0032727; P:positive regulation of interferon-alpha production; IDA:UniProtKB.
DR   GO; GO:0032728; P:positive regulation of interferon-beta production; IDA:UniProtKB.
DR   GO; GO:0061014; P:positive regulation of mRNA catabolic process; IDA:UniProtKB.
DR   GO; GO:1900246; P:positive regulation of RIG-I signaling pathway; IMP:UniProtKB.
DR   GO; GO:0032481; P:positive regulation of type I interferon production; IEA:Ensembl.
DR   GO; GO:0009615; P:response to virus; IDA:UniProtKB.
DR   GO; GO:0039507; P:suppression by virus of host molecular function; IEA:Ensembl.
DR   InterPro; IPR012317; Poly(ADP-ribose)pol_cat_dom.
DR   InterPro; IPR004170; WWE-dom.
DR   InterPro; IPR000571; Znf_CCCH.
DR   Pfam; PF00644; PARP; 1.
DR   Pfam; PF02825; WWE; 1.
DR   PROSITE; PS51059; PARP_CATALYTIC; 1.
DR   PROSITE; PS50918; WWE; 1.
DR   PROSITE; PS50103; ZF_C3H1; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Antiviral defense;
KW   Complete proteome; Cytoplasm; Immunity; Innate immunity;
KW   Metal-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; RNA-binding; Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895}.
FT   CHAIN         2    902       Zinc finger CCCH-type antiviral protein
FT                                1.
FT                                /FTId=PRO_0000211343.
FT   DOMAIN      594    681       WWE. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00248}.
FT   DOMAIN      716    902       PARP catalytic. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00397}.
FT   ZN_FING      73     86       C3H1-type 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00723}.
FT   ZN_FING      88    110       C3H1-type 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00723}.
FT   ZN_FING     150    172       C3H1-type 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00723}.
FT   ZN_FING     169    193       C3H1-type 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00723}.
FT   REGION        2    254       N-terminal domain.
FT   REGION      224    254       Binding to EXOSC5. {ECO:0000250}.
FT   MOTIF        69     76       Nuclear localization signal.
FT                                {ECO:0000250}.
FT   MOTIF       285    292       Nuclear export signal. {ECO:0000250}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895}.
FT   MOD_RES     257    257       Phosphoserine; by GSK3-beta.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     263    263       Phosphoserine; by GSK3-beta.
FT                                {ECO:0000250}.
FT   MOD_RES     267    267       Phosphoserine; by GSK3-beta.
FT                                {ECO:0000250}.
FT   MOD_RES     271    271       Phosphoserine; by GSK3-beta.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     273    273       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     275    275       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     284    284       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18220336,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     302    302       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     327    327       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q3UPF5}.
FT   MOD_RES     335    335       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     355    355       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     378    378       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     387    387       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332}.
FT   MOD_RES     393    393       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     407    407       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     469    469       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     492    492       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     494    494       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     554    554       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     590    590       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ       1    539       Missing (in isoform 4 and isoform 5).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|Ref.1}.
FT                                /FTId=VSP_010268.
FT   VAR_SEQ     491    624       DSLSDVTSTTSSRVDDHDSEEICLDHLCKGCPLNGSCSKVH
FT                                FHLPYRWQMLIGKTWTDFEHMETIEKGYCNPGIHLCSVGSY
FT                                TINFRVMSCDSFPIRRLSTPSSVTKPANSVFTTKWIWYWKN
FT                                ESGTWIQYGEE -> GKYKGKTLWASTFVHDIPNGSSQVVD
FT                                KTTDVEKTGATGFGLTMAVKAEKDMLCTGSQSLRNLVPTTP
FT                                GESTAPAQVSTLPQSPAALSSSNRAAVWGAQGQNCTQVPVS
FT                                SASELTRKTTGSAQCKSLKDKGASVS (in isoform
FT                                3). {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_010270.
FT   VAR_SEQ     625    902       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_010271.
FT   VAR_SEQ     699    902       DHQPAKTSSVSLTATFRPQEDFCFLSSKKYKLSEIHHLHPE
FT                                YVRVSEHFKASMKNFKIEKIKKIENSELLDKFTWKKSQMKE
FT                                EGKLLFYATSRAYVESICSNNFDSFLHETHENKYGKGIYFA
FT                                KDAIYSHKNCPYDAKNVVMFVAQVLVGKFTEGNITYTSPPP
FT                                QFDSCVDTRSNPSVFVIFQKDQVYPQYVIEYTEDKACVIS
FT                                -> E (in isoform 2 and isoform 5).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|Ref.1}.
FT                                /FTId=VSP_010269.
FT   VARIANT     485    485       R -> K (in dbSNP:rs2236426).
FT                                {ECO:0000269|PubMed:14702039}.
FT                                /FTId=VAR_018454.
FT   VARIANT     565    565       H -> Q (in dbSNP:rs2297241).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|Ref.1}.
FT                                /FTId=VAR_018455.
FT   VARIANT     701    701       Q -> E (in dbSNP:rs2297236).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:17974005}.
FT                                /FTId=VAR_054319.
FT   VARIANT     851    851       T -> I (in dbSNP:rs3735007).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:17974005}.
FT                                /FTId=VAR_018456.
FT   MUTAGEN     810    810       H->N: No effect on the structural
FT                                inability to bind NAD(+); when associated
FT                                with Y-830.
FT                                {ECO:0000269|PubMed:25635049}.
FT   MUTAGEN     830    830       N->Y: No effect on the structural
FT                                inability to bind NAD(+); when associated
FT                                with N-810.
FT                                {ECO:0000269|PubMed:25635049}.
FT   CONFLICT    245    245       A -> T (in Ref. 3; CAE11868).
FT                                {ECO:0000305}.
FT   STRAND      729    732       {ECO:0000244|PDB:2X5Y}.
FT   HELIX       738    748       {ECO:0000244|PDB:2X5Y}.
FT   STRAND      754    763       {ECO:0000244|PDB:2X5Y}.
FT   HELIX       765    778       {ECO:0000244|PDB:2X5Y}.
FT   STRAND      783    790       {ECO:0000244|PDB:2X5Y}.
FT   HELIX       791    793       {ECO:0000244|PDB:2X5Y}.
FT   HELIX       794    800       {ECO:0000244|PDB:2X5Y}.
FT   HELIX       804    807       {ECO:0000244|PDB:2X5Y}.
FT   STRAND      812    814       {ECO:0000244|PDB:2X5Y}.
FT   STRAND      816    823       {ECO:0000244|PDB:2X5Y}.
FT   HELIX       824    830       {ECO:0000244|PDB:2X5Y}.
FT   HELIX       835    837       {ECO:0000244|PDB:2X5Y}.
FT   STRAND      838    845       {ECO:0000244|PDB:2X5Y}.
FT   STRAND      849    852       {ECO:0000244|PDB:2X5Y}.
FT   STRAND      866    869       {ECO:0000244|PDB:2X5Y}.
FT   STRAND      871    873       {ECO:0000244|PDB:2X5Y}.
FT   STRAND      876    879       {ECO:0000244|PDB:2X5Y}.
FT   HELIX       882    884       {ECO:0000244|PDB:2X5Y}.
FT   STRAND      885    895       {ECO:0000244|PDB:2X5Y}.
SQ   SEQUENCE   902 AA;  101431 MW;  72AB311D23658E24 CRC64;
     MADPEVCCFI TKILCAHGGR MALDALLQEI ALSEPQLCEV LQVAGPDRFV VLETGGEAGI
     TRSVVATTRA RVCRRKYCQR PCDNLHLCKL NLLGRCNYSQ SERNLCKYSH EVLSEENFKV
     LKNHELSGLN KEELAVLLLQ SDPFFMPEIC KSYKGEGRQQ ICNQQPPCSR LHICDHFTRG
     NCRFPNCLRS HNLMDRKVLA IMREHGLNPD VVQNIQDICN SKHMQKNPPG PRAPSSHRRN
     MAYRARSKSR DRFFQGSQEF LASASASAER SCTPSPDQIS HRASLEDAPV DDLTRKFTYL
     GSQDRARPPS GSSKATDLGG TSQAGTSQRF LENGSQEDLL HGNPGSTYLA SNSTSAPNWK
     SLTSWTNDQG ARRKTVFSPT LPAARSSLGS LQTPEAVTTR KGTGLLSSDY RIINGKSGTQ
     DIQPGPLFNN NADGVATDIT STRSLNYKST SSGHREISSP RIQDAGPASR DVQATGRIAD
     DADPRVALVN DSLSDVTSTT SSRVDDHDSE EICLDHLCKG CPLNGSCSKV HFHLPYRWQM
     LIGKTWTDFE HMETIEKGYC NPGIHLCSVG SYTINFRVMS CDSFPIRRLS TPSSVTKPAN
     SVFTTKWIWY WKNESGTWIQ YGEEKDKRKN SNVDSSYLES LYQSCPRGVV PFQAGSRNYE
     LSFQGMIQTN IASKTQKDVI RRPTFVPQWY VQQMKRGPDH QPAKTSSVSL TATFRPQEDF
     CFLSSKKYKL SEIHHLHPEY VRVSEHFKAS MKNFKIEKIK KIENSELLDK FTWKKSQMKE
     EGKLLFYATS RAYVESICSN NFDSFLHETH ENKYGKGIYF AKDAIYSHKN CPYDAKNVVM
     FVAQVLVGKF TEGNITYTSP PPQFDSCVDT RSNPSVFVIF QKDQVYPQYV IEYTEDKACV
     IS
//
